Evidence map›Paper›PMID 36732606›Full record

ArticleScientific reports2023

The human microbial exposome: expanding the Exposome-Explorer database with gut microbial metabolites.

Vanessa Neveu, Geneviève Nicolas, Adam Amara, Reza M Salek, Augustin Scalbert

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Antibiotics (Basel, Switzerland) · 2024
    Review
  13. Review
  14. The potential importance of the built-environment microbiome and its impact on human health.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  15. Review
  16. Geospatial Science for the Environmental Epidemiology of Cancer in the Exposome Era.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Vanessa Neveu *Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), 25 avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France.
Geneviève Nicolas *Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), 25 avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France.
Adam AmaraNutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), 25 avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France.
Reza M SalekNutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), 25 avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France.
Augustin ScalbertNutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), 25 avenue Tony Garnier, CS 90627, 69366, Lyon Cedex 07, France. Scalbertaugustin@gmail.com.
Centre international de recherche sur le cancer · FR

Funding

World Health Organization 001
6 · The paper itself

Abstract

Metabolites produced by the gut microbiota play an important role in the cross-talk with the human host. Many microbial metabolites are biologically active and can pass the gut barrier and make it into the systemic circulation, where they form the gut microbial exposome, i.e. the totality of gut microbial metabolites in body fluids or tissues of the host. A major difficulty faced when studying the microbial exposome and its role in health and diseases is to differentiate metabolites solely or partially derived from microbial metabolism from those produced by the host or coming from the diet. Our objective was to collect data from the scientific literature and build a database on gut microbial metabolites and on evidence of their microbial origin. Three types of evidence on the microbial origin of the gut microbial exposome were defined: (1) metabolites are produced in vitro by human faecal bacteria; (2) metabolites show reduced concentrations in humans or experimental animals upon treatment with antibiotics; (3) metabolites show reduced concentrations in germ-free animals when compared with conventional animals. Data was manually collected from peer-reviewed publications and inserted in the Exposome-Explorer database. Furthermore, to explore the chemical space of the microbial exposome and predict metabolites uniquely formed by the microbiota, genome-scale metabolic models (GSMMs) of gut bacterial strains and humans were compared. A total of 1848 records on one or more types of evidence on the gut microbial origin of 457 metabolites was collected in Exposome-Explorer. Data on their known precursors and concentrations in human blood, urine and faeces was also collected. About 66% of the predicted gut microbial metabolites (n = 1543) were found to be unique microbial metabolites not found in the human GSMM, neither in the list of 457 metabolites curated in Exposome-Explorer, and can be targets for new experimental studies. This new data on the gut microbial exposome, freely available in Exposome-Explorer ( http://exposome-explorer.iarc.fr/ ), will help researchers to identify poorly studied microbial metabolites to be considered in future studies on the gut microbiota, and study their functionalities and role in health and diseases.

Indexed as

ExposomeGastrointestinal MicrobiomeAnimalsBacteriaDatabases, FactualData ManagementDietHumans

Identifiers

PMID36732606
PMCPMC9894932
OpenAlexW4318981447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.